FDA Approves Risperdal Consta for Treating Schizophrenia; First Long-Acting, Newer-Generation Antipsychotic Addresses Major Challenge of Schizophrenia Treatment.

AScribe Health News Service, October, 2003

Byline: Feinstein Kean Healthcare

TITUSVILLE, N.J., Oct. 30 (AScribe Newswire) -- The U.S. Food and Drug Administration (FDA) Wednesday approved Risperdal (R) Consta (TM) [(risperidone) long-acting injection] for the treatment of schizophrenia. It is the first long-acting, newer-generation (atypical) antipsychotic to be approved by the FDA. The treatment uses advanced technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks.

This addresses a major challenge in the treatment of schizophrenia (1) and helps patients, clinicians and families/caregivers know with certainty that patients receive needed medication for this serious brain disorder. As many as 75 percent of patients with...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.